Immunogen, Inc. (IMGN) Posts Q2 Loss of 29c/Share; Revs Light

Immunogen, Inc. (NASDAQ: IMGN) reported Q2 EPS of ($0.29), $0.04 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $2.6 million versus the consensus estimate of $6.02 million.

For earnings history and earnings-related data on Immunogen, Inc. (IMGN) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Axos Financial (AX) PT Raised to $120 at Benchmark
• Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation